Macro Group Pharmaceutical S.A.E. (Macro Capital) is specialized in developing, manufacturing and marketing pharmaceuticals. The company's products include anti-scar, skincare, antiseptic, hair care, oral care and muscle relaxant medicines. In addition, the group offers plant-based medicines. At the end of 2021, Macro Group Pharmaceutical S.A.E. (Macro Capital) had one production site in Egypt.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
11/06/26	1.210 £	0.00%	25,135,000
10/06/26	1.210 £	-4.72%	36,618,700
09/06/26	1.270 £	+0.79%	16,031,054
08/06/26	1.260 £	-1.56%	53,746,932
07/06/26	1.280 £	0.00%	31,887,071

End-of-day quote Egyptian Exchange

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Egyptian Exchange Other stock markets 11/06/2026			5-day change	1st Jan Change
1.210 ^EGP	0.00%		-5.47%	+6.14%

17/05	Macro Group Pharmaceutical Q1 consol profit egp 33.3 million	RE
20/02	Macro Group Pharmaceuticals (Macro Capital) S.A.E Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	690M 13.27M 11.47M 10.57M 9.89M 18.53M 1.26B 18.82M 125M 48.64M 614M 49.82M 48.76M 2.13B	P/E Ratio 2024	-33.1x	P/E Ratio 2025	5.7x
Enterprise Value	847M 16.3M 14.08M 12.98M 12.15M 22.76M 1.55B 23.11M 153M 59.74M 754M 61.19M 59.88M 2.61B	EV / Sales 2024	3.03x	EV / Sales 2025	0.9x
Free-Float	95.08%	Yield 2024 *	-	Yield 2025	-

17/05	Macro Group Pharmaceutical Q1 consol profit egp 33.3 million	RE
20/02	Macro Group Pharmaceuticals (Macro Capital) S.A.E Reports Earnings Results for the Full Year Ended December 31, 2025	CI
19/02	Macro Group Pharmaceutical FY consol profit EGP 115.7 mln	RE
19/11	Macro Group Pharmaceuticals (Macro Capital) S.A.E Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
13/11	Macro Group Pharmaceutical nine-month consol loss EGP 66.1 million	RE
12/10/25	Macro Group Pharmaceutical shareholders approve authorized capital increase to EGP 3 billion	RE
21/08/25	Macro Group Pharmaceuticals (Macro Capital) S.A.E Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
21/08/25	Macro Group Pharmaceutical posts Q2 consol profit EGP 46.5 mln	RE
21/08/25	Macro Group Pharmaceutical board approves renewal of EGP 100 mln short-term financing from KFH	RE
22/07/25	Macro Group Pharmaceutical board proposes capital increase	RE
10/06/25	Macro Group Pharmaceuticals (Macro Capital) S.A.E Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
10/04/25	MACRO Group Pharmaceutical's 328.6 Million Shares Block Traded For EGP 631 Million - EGX	RE
27/02/25	Macro Group Pharmaceuticals (Macro Capital) S.A.E Reports Earnings Results for the Full Year Ended December 31, 2024	CI

1 week	-5.47%
Current month	-3.20%
1 month	-6.92%
3 months	-11.68%
6 months	+6.14%
Current year	+6.14%

Macro Group Pharmaceuticals (Macro Capital) S.A.E Stock

Stocks

MCRO

EGS7D971C011

Pharmaceuticals

Valuation: Macro Group Pharmaceuticals (Macro Capital) S.A.E

Chart: Macro Group Pharmaceuticals (Macro Capital) S.A.E

Latest news : Macro Group Pharmaceuticals (Macro Capital) S.A.E

Quotes and Performance

Course Extremes

Managers and Directors: Macro Group Pharmaceuticals (Macro Capital) S.A.E

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	1.2	1.29
1 month	1.2	1.33
Current year	1.02	1.68
1 year	0.81	4.11
3 years	0.81	4.11
5 years	0.81	5.28
10 years	0.81	5.28

Manager	Title	Age	Since
Khaled Kamel CEO	Chief Executive Officer	-	-
Zeina Shahin IRC	Investor Relations Contact	-	-
Tamer Raouf SAM	Sales & Marketing	-	01/01/2022

Director	Title	Age	Since
Sahar El-Sallab BRD	Director/Board Member	-	01/01/2021
Ahmed Badreldin BRD	Director/Board Member	54	01/01/2021
Ahmed El-Nayeb CHM	Chairman	-	01/01/2002

	2024	2025
Net sales	520M 10M 8.64M 7.96M 7.45M 13.97M 951M 14.18M 94.02M 36.66M 463M 37.55M 36.75M 1.6B	895M 17.21M 14.87M 13.7M 12.82M 24.03M 1.64B 24.4M 162M 63.06M 796M 64.59M 63.22M 2.76B
Net income	-38.1M -733K -633K -583K -546K -1.02M -69.68M -1.04M -6.89M -2.69M -33.91M -2.75M -2.69M -117M	116M 2.23M 1.92M 1.77M 1.66M 3.11M 212M 3.16M 20.93M 8.16M 103M 8.36M 8.18M 357M
Net Debt	254M 4.89M 4.22M 3.89M 3.64M 6.82M 464M 6.93M 45.92M 17.91M 226M 18.34M 17.95M 783M	157M 3.03M 2.62M 2.41M 2.26M 4.23M 288M 4.29M 28.46M 11.1M 140M 11.37M 11.12M 485M

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MACRO GROUP PHARMACEUTICALS (MACRO CAPITAL) S.A.E	0.00%	-5.47%	-44.75%	-59.67%	13.27M
ELI LILLY AND COMPANY	-2.41%	+0.14%	+38.28%	+154.20%	1,010B
JOHNSON & JOHNSON	+1.07%	+3.48%	+53.32%	+49.85%	580B
ABBVIE INC.	+1.32%	+0.22%	+19.18%	+64.65%	402B
ROCHE HOLDING AG	+0.77%	0.00%	+21.28%	+16.70%	330B
NOVARTIS AG	+0.44%	+3.48%	+25.65%	+35.66%	281B
ASTRAZENECA PLC	-0.85%	-2.86%	+22.54%	+14.67%	280B
NOVO NORDISK A/S	+1.66%	+1.20%	-44.35%	-47.35%	197B
AMGEN INC.	+0.32%	+1.61%	+20.32%	+60.01%	192B
GILEAD SCIENCES, INC.	-0.22%	-2.76%	+14.19%	+60.09%	156B
Average	+0.21%	+0.21%	+12.57%	+34.88%	342.89B
Weighted average by Cap.	-0.23%	+1.04%	+27.77%	+70.54%